Personalis, Tempus AI Expand Collaboration to Biopharma Industry

MT Newswires Live

2024/12/17

Personalis (PSNL) and Tempus AI (TEM) said Monday they have expanded their collaboration to the biopharma industry.

Tempus is the exclusive commercial diagnostic partner for Personalis' NeXT Personal Dx minimal residual disease product for broad patient adoption in breast and lung cancers, as well as for immunotherapy monitoring across all solid tumors.

The expanded collaboration allows Tempus to offer the product to pharmaceutical and biotech customers who are looking to bundle minimal residual disease testing with other Tempus offerings in a given study, the companies said.

Price: 3.90, Change: +0.08, Percent Change: +2.09

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2492619509"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492619509\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2492619509?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-17 00:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492619509","market":"sg","top_or_hot":-1,"title":"Personalis, Tempus AI Expand Collaboration to Biopharma Industry","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PSNL\">Personalis</a> (PSNL) and <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> (TEM) said Monday they have expanded their collaboration to the biopharma industry.</p><p>Tempus is the exclusive commercial diagnostic partner for Personalis' NeXT Personal Dx minimal residual disease product for broad patient adoption in breast and lung cancers, as well as for immunotherapy monitoring across all solid tumors.</p><p>The expanded collaboration allows Tempus to offer the product to pharmaceutical and biotech customers who are looking to bundle minimal residual disease testing with other Tempus offerings in a given study, the companies said.</p><p>Price: 3.90, Change: +0.08, Percent Change: +2.09</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Personalis, Tempus AI Expand Collaboration to Biopharma Industry</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPersonalis, Tempus AI Expand Collaboration to Biopharma Industry\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-17 00:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PSNL\">Personalis</a> (PSNL) and <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> (TEM) said Monday they have expanded their collaboration to the biopharma industry.</p><p>Tempus is the exclusive commercial diagnostic partner for Personalis' NeXT Personal Dx minimal residual disease product for broad patient adoption in breast and lung cancers, as well as for immunotherapy monitoring across all solid tumors.</p><p>The expanded collaboration allows Tempus to offer the product to pharmaceutical and biotech customers who are looking to bundle minimal residual disease testing with other Tempus offerings in a given study, the companies said.</p><p>Price: 3.90, Change: +0.08, Percent Change: +2.09</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEM","symbol_name":"Tempus AI","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2492619509","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492619509","pubTimestamp":1734366333,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Personalis  and Tempus AI  said Monday they have expanded their collaboration to the biopharma industry.Tempus is the exclusive commercial diagnostic partner for Personalis' NeXT Personal Dx minimal residual disease product for broad patient adoption in breast and lung cancers, as well as for immunotherapy monitoring across all solid tumors.The expanded collaboration allows Tempus to offer the product to pharmaceutical and biotech customers who are looking to bundle minimal residual disease testing with other Tempus offerings in a given study, the companies said.Price: 3.90, Change: +0.08, Percent Change: +2.09","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEM":"Tempus AI","BK4121":"生命科学工具和服务","PSNL":"Personalis","BK7095":"多种金属与采矿","TEM.AU":"TEMPEST MINERALS LTD"},"translate_title":"Personalis与Tempus AI将合作扩展到生物制药行业","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":1,"PSNL":1,"TEM.AU":1},"content_text":"Personalis (PSNL) and Tempus AI (TEM) said Monday they have expanded their collaboration to the biopharma industry.Tempus is the exclusive commercial diagnostic partner for Personalis' NeXT Personal Dx minimal residual disease product for broad patient adoption in breast and lung cancers, as well as for immunotherapy monitoring across all solid tumors.The expanded collaboration allows Tempus to offer the product to pharmaceutical and biotech customers who are looking to bundle minimal residual disease testing with other Tempus offerings in a given study, the companies said.Price: 3.90, Change: +0.08, Percent Change: +2.09","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}